<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">46112</article-id><article-id pub-id-type="doi">10.7554/eLife.46112</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>An engineered monomer binding-protein for α-synuclein efficiently inhibits the proliferation of amyloid fibrils</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-131908"><name><surname>Agerschou</surname><given-names>Emil Dandanell</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-102865"><name><surname>Flagmeier</surname><given-names>Patrick</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1204-5340</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-135622"><name><surname>Saridaki</surname><given-names>Theodora</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-135624"><name><surname>Galvagnion</surname><given-names>Céline</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-135630"><name><surname>Komnig</surname><given-names>Daniel</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6312-5236</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-135621"><name><surname>Heid</surname><given-names>Laetitia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-135631"><name><surname>Prasad</surname><given-names>Vibha</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-94437"><name><surname>Shaykhalishahi</surname><given-names>Hamed</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-94438"><name><surname>Willbold</surname><given-names>Dieter</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0065-7366</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-8142"><name><surname>Dobson</surname><given-names>Christopher M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-135632"><name><surname>Voigt</surname><given-names>Aaron</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0428-7462</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-135623"><name><surname>Falkenbürger</surname><given-names>Björn</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-152636"><name><surname>Hoyer</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-80252"><name><surname>Buell</surname><given-names>Alexander K</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1161-3622</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Institute of Physical Biology</institution>, <institution>Heinrich Heine University Düsseldorf</institution>, <addr-line><named-content content-type="city">Düsseldorf</named-content></addr-line>, <country>Germany</country></aff><aff id="aff2"><institution content-type="dept">Department of Chemistry</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution content-type="dept">Department of Neurology</institution>, <institution>RWTH Aachen University</institution>, <addr-line><named-content content-type="city">Aachen</named-content></addr-line>, <country>Germany</country></aff><aff id="aff4"><institution content-type="dept">Biotechnology and Biomedicine</institution>, <institution>Technical University of Denmark</institution>, <addr-line><named-content content-type="city">Kgs Lyngby</named-content></addr-line>, <country>Denmark</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-64900"><name><surname>West</surname><given-names>Andrew B</given-names></name><role>Reviewing editor</role><aff><institution>Duke University</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>bfalkenburger@ukaachen.de</email> (BF);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>wolfgang.hoyer@hhu.de</email> (WH);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>alebu@dtu.dk</email> (AB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>07</day><month>08</month><year>2019</year></pub-date><volume>8</volume><elocation-id>e46112</elocation-id><history><date date-type="received"><day>25</day><month>02</month><year>2019</year></date><date date-type="accepted"><day>04</day><month>08</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Agerschou et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Agerschou et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-46112-v1.pdf"/><abstract><p>Removing or preventing the formation of α-synuclein aggregates is a plausible strategy against Parkinson's disease. To this end we have engineered the β-wrapin AS69 to bind monomeric α-synuclein with high affinity. In cultured cells, AS69 reduced the self-interaction of α-synuclein and the formation of visible α-synuclein aggregates. In flies, AS69 reduced α-synuclein aggregates and the locomotor deficit resulting from α-synuclein expression in neuronal cells. In biophysical experiments in vitro, AS69 highly sub-stoichiometrically inhibited both primary and autocatalytic secondary nucleation processes, even in the presence of a large excess of monomer. We present evidence that the AS69-α-synuclein complex, rather than the free AS69, is the inhibitory species responsible for sub-stoichiometric inhibition of secondary nucleation. These results represent a new paradigm that high affinity monomer binders can lead to strongly sub-stoichiometric inhibition of nucleation processes.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>D. melanogaster</italic></kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000275</institution-id><institution>Leverhulme Trust</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Buell</surname><given-names>Alexander K</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001645</institution-id><institution>Boehringer Ingelheim Fonds</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Flagmeier</surname><given-names>Patrick</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004350</institution-id><institution>Studienstiftung des Deutschen Volkes</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Flagmeier</surname><given-names>Patrick</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005156</institution-id><institution>Alexander von Humboldt-Stiftung</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Galvagnion</surname><given-names>Céline</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010663</institution-id><institution>H2020 European Research Council</institution></institution-wrap></funding-source><award-id>726368</award-id><principal-award-recipient><name><surname>Galvagnion</surname><given-names>Céline</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Parkinson's and Movement Disorder Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Buell</surname><given-names>Alexander K</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000780</institution-id><institution>European Commission</institution></institution-wrap></funding-source><award-id>706551</award-id><principal-award-recipient><name><surname>Galvagnion</surname><given-names>Céline</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution>Novo Nordisk Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Buell</surname><given-names>Alexander K</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>- Numerical data represented in the graphs for cell culture and fly experiments will be made publicly available on osf.io as we did for previous publications.- The numerical data for the biophysical experiments will be made publicly available within the same repository on osf.io.- The raw images of the gels used in the publication will be made publicly available.All data have been deposited on osf.io ( https://osf.io/6n2gs/?view_only=7eb7024d8ecb460a817cd0ed35978339 ) and will be made available in the event of publication</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Falkenburger BH</collab><collab>Buell AK</collab><collab>Agerschou ED</collab></person-group><year iso-8601-date="2019">2019</year><source>An engineered monomer binding-protein for &amp;#x1D6FC;-synuclein efficiently inhibits the nucleation of amyloid fibrils</source><ext-link ext-link-type="uri" xlink:href="https://osf.io/6n2gs/?view_only=7eb7024d8ecb460a817cd0ed35978339">https://osf.io/6n2gs/?view_only=7eb7024d8ecb460a817cd0ed35978339</ext-link><comment>OSF</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-46112-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>